Multiple Ascending Dose Study of DS-1093 in Healthy Subjects

Summary

This is a randomised, double-blind, placebo-controlled multiple ascending single study. It is hypothesised that at least dose of DS-1093a will be safe and tolerable over a 2-week treatment period and will result in increases in reticulocyte count and haemoglobin concentrations in healthy male volunteers

Timeline

Start

2014-05

Primary completion

2015-02

Completion

2015-02

Drugs

Indications